PPARA and type 2 diabetes mellitus: Dual PPARα/γ agonists that were developed to target hyperlipidaemia and hyperglycaemia in type 2 diabetes patients, caused cardiac dysfunction or other adverse effects as fluid retention and body-weight gain.